Private equity firm TPG Capital Asia is close to an agreement to sell a minority stake in Pathology Asia Holdings Pte in a deal that values the health-care business at about $2 billion, according to people with knowledge of the matter.
Government-backed investors from Asia and the Middle East are among parties interested in taking a stake in Pathology Asia, said the people, who asked not to be identified as the information is private. The buyout firm could agree to sell a little less than 30% of the unit to potential investors as soon as the end of this month, one of the people said.
TPG has invested more than $13 billion in companies including jeweler APM Monaco, clinical research firm Novotech and the Indian conglomerate Shriram Group, its website shows.
Read more/Source: BNN Bloomberg
